Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company. Already ...
AstraZeneca's ambitious $80 billion revenue goal by 2030 hinges on oncology growth and successful new drug launches, but faces patent expiries and fierce competition. While current financials and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results